Skip to main content
Premium Trial:

Request an Annual Quote

BioTrove Raises $10.9M in Financing

NEW YORK, Jan. 29 (GenomeWeb News) - BioTrove said today it has raised $10.9 million in financing to develop its Living Chip technology and assays.

 

Investors in the round include Catalyst Health and Technology Partners, CB Health Ventures, Zero Stage Capital, and BioFrontier Partners.

 

The company, based in Woburn, Mass., is aiming its Living Chip technology, a nano-fluidics platform, at analysis of genomic, proteomic, cellular, and other biochemical samples. It also is developing a mass spectrometry service, Momentum Assay Development and Screening, for microliter-scale assays and screening.

 

The company also said it has appointed to its board of directors Ben Bronstein, amanaging director at Zero Stage Capital.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.